Hepion Pharmaceuticals, Inc. financial data

Symbol
HEPA on Nasdaq, CTRVP on OTC
Industry
Pharmaceutical Preparations
Location
399 Thornall Street, First Floor, Edison, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
ContraVir Pharmaceuticals, Inc. (to 7/23/2019)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 363 % -26.3%
Debt-to-equity 144 % +347%
Return On Equity -506 % -267%
Return On Assets -207 % -98.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.96M shares +60.4%
Common Stock, Shares, Outstanding 6.96M shares +81.3%
Entity Public Float 40.3M USD -7.14%
Common Stock, Value, Issued 663 USD +72.7%
Weighted Average Number of Shares Outstanding, Basic 6.72M shares +75.1%
Weighted Average Number of Shares Outstanding, Diluted 6.72M shares +75.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 17.9M USD -52.6%
General and Administrative Expense 7.48M USD -25.9%
Operating Income (Loss) -28.6M USD +40.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -26.1M USD +45.2%
Income Tax Expense (Benefit) -3.38M USD -17.1%
Net Income (Loss) Attributable to Parent -22.7M USD +49.2%
Earnings Per Share, Basic -4.38 USD/shares +65%
Earnings Per Share, Diluted -4.38 USD/shares +65%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 3.53M USD -83.4%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 118K USD -51.2%
Goodwill 0 USD -100%
Other Assets, Noncurrent 66.5K USD
Assets 3.72M USD -85.1%
Accounts Payable, Current 186K USD -93.8%
Employee-related Liabilities, Current 0 USD -100%
Accrued Liabilities, Current 306K USD -89.5%
Liabilities, Current 2.72M USD -57.6%
Deferred Income Tax Liabilities, Net 0 USD -100%
Operating Lease, Liability, Noncurrent 41.2K USD
Liabilities 4.12M USD -53.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -53.8K USD +42.7%
Retained Earnings (Accumulated Deficit) -236M USD -10.6%
Stockholders' Equity Attributable to Parent -407K USD -103%
Liabilities and Equity 3.72M USD -85.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.62M USD +56%
Net Cash Provided by (Used in) Financing Activities 1.85M USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 6.96M shares +81.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.68M USD +79.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.5M USD -92.2%
Deferred Tax Assets, Valuation Allowance 44.5M USD +43.2%
Deferred Tax Assets, Gross 44.6M USD +40.8%
Operating Lease, Liability 118K USD -51.2%
Depreciation 75.9K USD -20.8%
Payments to Acquire Property, Plant, and Equipment 0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -22.7M USD +49.3%
Lessee, Operating Lease, Liability, to be Paid 139K USD -46.9%
Operating Lease, Liability, Current 118K USD +5.05%
Lessee, Operating Lease, Liability, to be Paid, Year Two 97.8K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 97.8K USD -28.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure +123%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 21.3K USD +2.97%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Depreciation, Depletion and Amortization 30.8K USD +70.5%
Deferred Tax Assets, Net of Valuation Allowance 62.5K USD -88.9%
Share-based Payment Arrangement, Expense 913K USD -63.4%
Interest Expense 11.5K USD +11.8%